Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY MYCITE KIT vs EPANED KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.
Vitamin B12 (cobalamin) is a cofactor for methionine synthase and methylmalonyl-Co A mutase, essential for DNA synthesis, myelin formation, and hematopoiesis. It also reduces homocysteine levels.
Schizophrenia,Acute manic/mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Treatment of pernicious anemia and vitamin B12 deficiency due to malabsorption (e.g., gastrectomy, Crohn's disease, intrinsic factor deficiency),Maintenance therapy for B12 deficiency after initial parenteral treatment,Off-label: hyperhomocysteinemia, cognitive decline, neuropathy (not FDA approved)
Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.
Intravenous: 0.5-1 mg/kg/dose (max 50 mg/dose) every 6 hours as needed for nausea and vomiting.
Aripiprazole: 75 hours (range 48–146 h). Dehydro-aripiprazole: 94 hours (range 48–206 h). Steady state reached in 14 days.
Terminal elimination half-life: 2.4–3.2 hours in healthy adults; prolonged to 5–10 hours in hepatic impairment; clinically relevant for dosing interval adjustment.
Aripiprazole is metabolized primarily by CYP2D6 and CYP3A4. The major active metabolite is dehydro-aripiprazole (formed by CYP2D6). Phase I reactions include dehydrogenation and hydroxylation. Phase II glucuronidation of hydroxylated metabolites occurs.
Hydroxocobalamin is converted to methylcobalamin and adenosylcobalamin in the liver. It undergoes enterohepatic recycling and is primarily excreted unchanged in bile, with minimal renal excretion.
Aripiprazole: ~25% renal, ~55% fecal; unchanged drug accounts for <1% renal. Dehydro-aripiprazole (active metabolite): excreted similarly.
Renal: 50-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; minimal respiratory excretion.
Aripiprazole: >99% bound to albumin and alpha-1-acid glycoprotein. Dehydro-aripiprazole: >99% bound.
90–95% primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Aripiprazole: 4.9 L/kg (IV). High Vd indicates extensive tissue distribution.
0.3–0.5 L/kg; indicates distribution mainly into extracellular fluid and well-perfused tissues.
Oral: 87% (absolute). Tablet and orally disintegrating tablet are bioequivalent.
Intravenous: 100%; intramuscular: 75–85%; oral: 40–60% (first-pass effect).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). Not recommended for severe renal impairment (Cr Cl <15 m L/min) due to lack of data.
GFR 10-50 m L/min: No adjustment. GFR <10 m L/min: Not recommended due to propylene glycol accumulation.
Child-Pugh Class A or B: No dose adjustment necessary. Child-Pugh Class C: Use with caution; maximum dose 10 mg/day due to increased exposure.
Child-Pugh Class A: No adjustment. Child-Pugh Class B or C: Maximum 150 mg/day (total daily dose) due to reduced clearance.
Not approved for patients <18 years; safety and effectiveness not established.
Children 2-12 years: 0.5-1 mg/kg/dose (max 25 mg/dose) IV every 6 hours. Infants <2 years: 0.5 mg/kg/dose IV every 6 hours. Not recommended for neonates.
No specific dose adjustment; use lower starting doses (e.g., 5 mg/day) due to increased sensitivity and risk of adverse effects, especially orthostatic hypotension and tardive dyskinesia.
No specific dose adjustment, but consider reduced clearance; use lowest effective dose and monitor for anticholinergic effects.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.
No black box warning.
Neuroleptic malignant syndrome,Tardive dyskinesia,Metabolic changes including hyperglycemia/diabetes, dyslipidemia, weight gain,Orthostatic hypotension,Falls,Leukopenia/neutropenia/agranulocytosis,Seizures,Body temperature regulation impairment,Dysphagia,Suicidal thoughts/behaviors in adolescents/young adults with MDD
May cause hypokalemia and increased platelet count during initial treatment of pernicious anemia; monitor potassium levels.,Avoid in patients with cobalt hypersensitivity (cobalt is a component of hydroxocobalamin).,Not suitable for leber's disease (hereditary optic nerve atrophy) due to risk of optic atrophy.,May interact with nitrous oxide (inactivates cobalamin) and chloramphenicol (antagonizes hematologic response).
Hypersensitivity to aripiprazole or any component of the formulation,Concurrent use with ziprasidone (QT prolongation risk)
Hypersensitivity to hydroxocobalamin, cyanocobalamin, or cobalt,Leber's disease (hereditary optic nerve atrophy)
No specific food interactions are reported for the sensor component. Aripiprazole can be taken with or without food. However, avoid excessive alcohol consumption as it may increase central nervous system depression or worsen side effects. Grapefruit and grapefruit juice do not significantly interact with aripiprazole metabolism (CYP3A4 minor pathway); no restriction needed.
No specific food interactions with epinephrine. Diphenhydramine may be taken with or without food. Avoid alcohol while taking diphenhydramine due to additive sedative effects. Patients with certain food allergies (e.g., peanut, egg) should ensure the device components are free of allergens; EPANED KIT contains no known food allergens.
First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimester: Neonates exposed to antipsychotics (including aripiprazole) during late pregnancy may experience extrapyramidal symptoms and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder).
EPANED KIT (hydroxyprogesterone caproate) is a progestin. First trimester: No evidence of increased risk of major birth defects based on clinical studies and postmarketing surveillance, but animal studies with high doses showed some developmental effects. Second and third trimesters: No teratogenic effects; used to reduce risk of preterm birth. Long-term follow-up of exposed children shows no increased rate of congenital anomalies.
Aripiprazole is present in human breast milk; limited data suggest infant serum levels are low but can vary. M/P ratio not established. Caution advised; monitor infant for sedation, irritability, and feeding problems.
Minimal excretion into breast milk is expected. The M/P ratio is not established. Use with caution; hydroxyprogesterone caproate may decrease milk production. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for the drug.
No specific dose adjustment recommended; however, pregnancy may alter aripiprazole pharmacokinetics (decreased exposure due to increased volume of distribution and clearance). Monitor clinical response and consider dose adjustment if efficacy or tolerability changes. Use lowest effective dose.
No dose adjustments required for pregnancy-induced pharmacokinetic changes. Standard dosing is 250 mg (1 m L) intramuscularly once weekly starting at 16 weeks 0 days through 20 weeks 6 days and continuing until 37 weeks 6 days or delivery, whichever occurs first.
Abilify My Cite is aripiprazole tablets embedded with an ingestible sensor (Ingestible Event Marker, IEM) that communicates with a wearable patch to record medication ingestion. It is used for schizophrenia, bipolar I disorder, and as adjunctive therapy for major depressive disorder. The sensor does not monitor drug levels or efficacy; it only confirms ingestion. Ensure the patient has a compatible smartphone and the My Cite app. The patch must be replaced weekly. Avoid MRI, CT, or diathermy near the patch; remove if undergoing these procedures. Monitor for aripiprazole side effects: akathisia, metabolic changes, tardive dyskinesia, and neuroleptic malignant syndrome. The ingestible sensor contains copper, magnesium, and silicon; allergy risk is low but possible.
EPANED KIT contains epinephrine (for anaphylaxis) and diphenhydramine (for allergic symptoms). Epinephrine is the first-line treatment for anaphylaxis; administer intramuscularly in the anterolateral thigh. Use with caution in patients with cardiovascular disease, hyperthyroidism, or diabetes. Monitor for rebound anaphylaxis and delayed biphasic reactions. The antihistamine component may cause sedation.
Take Abilify My Cite by mouth as directed. The sensor in the tablet activates upon contact with stomach fluid. Wear the My Cite patch on your left upper abdomen, replacing it weekly. Use the My Cite app to scan the tablet's QR code and confirm ingestion. Do not crush or chew the tablet. If a dose is missed, take it as soon as remembered unless it is close to the next dose. Do not double doses.,The patch is not MRI compatible; remove it before any MRI, CT scan, or diathermy procedure. Inform all healthcare providers that you use this system. The patch contains no latex. You may feel a mild sensation when the patch communicates with your phone. Keep your phone nearby (within Bluetooth range) for recording.,Common side effects of aripiprazole include nausea, vomiting, constipation, headache, dizziness, insomnia, restlessness, and weight gain. Seek medical attention for severe muscle stiffness, fever, confusion, irregular heartbeat, or suicidal thoughts. Avoid alcohol and activities requiring mental alertness until you know how this medication affects you.,The ingestible sensor is generally safe, but if you have a sensitivity to copper, magnesium, or silicon, discuss with your doctor. The patch may cause skin irritation; if it persists, stop use and contact your provider.,Do not rely solely on the app to confirm ingestion; it is not a substitute for clinical judgment. Store tablets at room temperature, away from moisture and heat. Keep out of reach of children.
Use the epinephrine auto-injector immediately at the first sign of a severe allergic reaction, even if you are unsure.,Inject into the outer thigh, through clothing if necessary. Do not inject into a vein or buttock.,Seek emergency medical help immediately after using the device. The antihistamine does not replace epinephrine.,Avoid activities requiring alertness until you know how the antihistamine affects you; it may cause drowsiness.,Store at room temperature, protect from light and freezing. Check expiration dates regularly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY MYCITE KIT vs EPANED KIT, answered by our medical review team.
ABILIFY MYCITE KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.. EPANED KIT is a Vasopressor that works by Vitamin B12 (cobalamin) is a cofactor for methionine synthase and methylmalonyl-Co A mutase, essential for DNA synthesis, myelin formation, and hematopoiesis. It also reduces homocysteine levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY MYCITE KIT and EPANED KIT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY MYCITE KIT is: Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.. The standard adult dose of EPANED KIT is: Intravenous: 0.5-1 mg/kg/dose (max 50 mg/dose) every 6 hours as needed for nausea and vomiting.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY MYCITE KIT and EPANED KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY MYCITE KIT is classified as Category C. First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimes. EPANED KIT is classified as Category C. EPANED KIT (hydroxyprogesterone caproate) is a progestin. First trimester: No evidence of increased risk of major birth defects based on clinical studies and postmarketing surveill. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.